Literature DB >> 9565722

Reassurance therapy: what to say to symptomatic patients with benign or non-existent medical disease.

R G Kathol1.   

Abstract

Reassurance is one of the most important therapies that primary care physicians give; however, little has been written about it in the literature. This article suggests six steps needed for effective reassurance in patients with benign disease or symptoms not explained by disease. These include; 1) question and examine the patient, 2) assure the patient that serious illness is not present, 3) suggest the symptom will resolve, 4) tell the patient to return to normal activity, 5) consider non-specific treatment, and 6) follow the patient Only if these systematic steps are followed will reassurance consistently work. Since examination of the patient is a critical component of reassurance therapy, it can most effectively be administered by individuals who include a physical assessment as a part of the clinical evaluation.

Entities:  

Mesh:

Year:  1997        PMID: 9565722     DOI: 10.2190/KBCC-PDRC-W93L-870J

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  4 in total

Review 1.  The somatizing patient.

Authors:  V Holder-Perkins; T Wise; D E Williams
Journal:  Curr Psychiatry Rep       Date:  2000-06       Impact factor: 5.285

2.  Normalisation of unexplained symptoms by general practitioners: a functional typology.

Authors:  Christopher F Dowrick; Adele Ring; Gerry M Humphris; Peter Salmon
Journal:  Br J Gen Pract       Date:  2004-03       Impact factor: 5.386

3.  Auriculotemporal Frey syndrome not associated with surgery or diabetes: systematic review.

Authors:  Céline Betti; Gregorio P Milani; Sebastiano A G Lava; Mario G Bianchetti; Gabriel Bronz; Gian P Ramelli; Barbara Goeggel Simonetti; Marcel M Bergmann
Journal:  Eur J Pediatr       Date:  2022-02-19       Impact factor: 3.860

4.  Reassurance and the anxious cancer patient.

Authors:  D Stark; M Kiely; A Smith; S Morley; P Selby; A House
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.